Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PHARMACEUTICAL COMPOSITION COMPRISING HTR2A ANTAGONIST AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING FATTY LIVER
Document Type and Number:
WIPO Patent Application WO/2018/174379
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition comprising an HTR2A inhibitor as an effective ingredient for preventing or treating fatty liver. Being inhibitive of high fat diet-induced fatty liver production and suppressive of the expression of lipogenesis-related genes in hepatocytes, the HTR2A inhibitor of the present invention can be useful as an effective ingredient in a composition for prevention or treatment of fatty liver, and the like.

Inventors:
KIM HA IL (KR)
NAMKUNG JUN (KR)
CHOI WON SUK (KR)
Application Number:
PCT/KR2017/015006
Publication Date:
September 27, 2018
Filing Date:
December 19, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
KOREA ADVANCED INST SCI & TECH (KR)
International Classes:
A61K31/517; A23L33/10; A23L33/13; A61K48/00; C12Q1/68; G01N33/50
Foreign References:
KR101519448B12015-05-13
KR20160108258A2016-09-19
US20150024995A12015-01-22
Other References:
FU, JIHUA: "Long-term stress with hyperglucocorticoidemia-induced hepatic steatosis with VLDL overproduction is dependent on both 5-HT2 receptor and 5-HT synthesis in liver", INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, vol. 12, no. 2, 1 January 2016 (2016-01-01), pages 219 - 234, XP055608750, ISSN: 1449-2288, DOI: 10.7150/ijbs.13062
PEREZ-CORNAGO, AUROR A: "DNA hypermethylation of the serotonin receptor type-2A gene is associated with a worse response to a weight loss intervention in subjects with metabolic syndrome", NUTRIENTS, vol. 6, no. 6, 23 June 2014 (2014-06-23), pages 2387 - 2403, XP055608753, DOI: 10.3390/nu6062387
Attorney, Agent or Firm:
YOON, Dae Woong (KR)
Download PDF: